Dosing has started in the second cohort of an ongoing phase 1 clinical trial of gene therapy candidate ADVM-022 for the treatment of wet age-related macular degeneration, Adverum Biotechnologies announced in a press release.
The second cohort of the multicenter, open-label OPTIC trial is receiving an intravitreal injection with a dose of ADVM-022 of 2 × 1012 vg per eye. Safety and tolerability of ADVM-022 at 24 weeks are the study’s primary endpoints.
“We believe ADVM-022 has potential to provide sustained therapeutic benefit with a single intravitreal injection to patients living with wet AMD. In the first cohort of patients, we have seen a robust preliminary anatomical response and no serious adverse events to date,” Aaron Osborne, MBBS, MRCOphth, Adverum chief medical officer, said in the release.